A Study Of Biospecimens On PARP Inhibitor-Associated Myeloid Neoplasms

Overview

About this study

The purpose of this study is to assess ex vivo sensitivity of TMNs arising during PARP inhibitor therapy to selected therapeutic agents, including decitabine, venetoclax, A1331852, S63845, prexasertib, adavosertib, ceralasertib, eprenetapopt, pevonedistat, magrolimab, and sabatolimab, both as single agents and in combination.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Age ≥18 years
Prior treatment with a PARP inhibitor for cancer with a focus on ovarian cancer
Suspected or confirmed therapy-related myeloid neoplasm
Undergoing clinically indicated bone marrow aspirate/biopsy
Able to provide informed consent, or consent provided by a legally authorized representative when allowed
Willing to allow collection of relevant clinical data and biospecimen banking under this protocol

Exclusion Criteria:

Age < 18 years

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 04/13/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Scott Kaufmann, M.D., Ph.D.	Open for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Scott Kaufmann, M.D., Ph.D.

Open for enrollment

More information

Publications

Publications are currently not available

Clinical Trials